Physicians' Academy for Cardiovascular Education

Lessons from Landmark trials with PCSK9i

This educational series aims to provide guidance on Lessons from PCSK9i landmark trials on why, who and how to manage patients at increased CV risk. (also as CME)

Lessons from landmark trials with PCSK9i: Why, who and how to manage patients at increased CV risk?

EBAC-accredited E-Learning

Online-CME - This course consists of 4 separate lectures
This course consists of 4 separate lectures

CME accredited course focussed on the role of PCSK9 inhibitors in the management of patients at increased CV risk. Member registration (free) is needed to enroll in this course

Identifying patients for PCSK9 therapy

PCSK9: Outcomes and trials in clinical perspective

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME
PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

PCSK9: Outcomes and trials in clinical perspective PCSK9 inhibitors should be mainly considered for the highest risk categories on maximally tolerated statin plus ezetimibe. Prof. Kees Hovingh discusses how to identify these high risk patients.

Guidelines and the role of non-statin therapies for high risk ASCVD patients

PCSK9: Outcomes and trials in clinical perspective

10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME
There is still a high (residual) risk for future events in many high risk ASCVD patients, despite maximally tolerated statin therapy. Prof. Jukema discusses the use of PCSK9 inhibitors in these high risk patients and the recommendations from international guidelines.

PCSK9: Outcomes and trials in clinical perspective There is still a high (residual) risk for future events in many high risk ASCVD patients, despite maximally tolerated statin therapy. Prof. Jukema discusses the use of PCSK9 inhibitors in these high risk patients and the recommendations from international guidelines.

Landmark trials with PCSK9 inhibitors

PCSK9: Outcomes and trials in clinical perspective

10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME
Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

PCSK9: Outcomes and trials in clinical perspective Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

PCSK9 inhibitors: How do they work?

PCSK9: Outcomes and trials in clinical perspective

10' education - Dec. 4, 2018 - John Chapman - Paris, France - Online CME
Prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.

PCSK9: Outcomes and trials in clinical perspective Prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.

Lessons from Landmark trials with PCSK9i